Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.
Cosson V, Fu R, Kulasekararaj A, Nishimura JI, Panse J, Röth A, Scheinberg P, Tong H, Yoon SS, Beveridge L, Gotanda K, Jaminion F, Henrich A, Lundberg P, Shi D, Sreckovic S, Zhang Y, Zhang Z, Benkali K, Buatois S. Cosson V, et al. Among authors: kulasekararaj a. Br J Clin Pharmacol. 2025 Jan 21. doi: 10.1111/bcp.16394. Online ahead of print. Br J Clin Pharmacol. 2025. PMID: 39835421
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH.
Kulasekararaj AG, Griffin M, Piatek CI, Shammo J, Nishimura JI, Patriquin CJ, Schrezenmeier H, Barcellini W, Panse JP, Gaya A, Patel Y, Liu P, Filippov G, Sicre de Fontbrune F, Risitano AM, Lee JW. Kulasekararaj AG, et al. Blood. 2024 Dec 19:blood.2024026299. doi: 10.1182/blood.2024026299. Online ahead of print. Blood. 2024. PMID: 39700502
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.
da Fonseca ARB, Justino CC, de Molla VC, Yamakawa PE, Rabelo IB, Arnold LM, Kelly RJ, Griffin M, Munir T, Hill A, Velloso EDRP, Dalessandro T, Risitano AM, Scheinberg P, Kulasekararaj AG, Arrais-Rodrigues C. da Fonseca ARB, et al. Among authors: kulasekararaj ag. Blood Adv. 2024 Dec 18:bloodadvances.2024014159. doi: 10.1182/bloodadvances.2024014159. Online ahead of print. Blood Adv. 2024. PMID: 39693508
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, Panse J, Pullarkat V, Röth A, Shammo J, Terriou L, Weitz I, Yermilov I, Gibbs S, Broder M, Beenhouwer D, Kuter D. Dingli D, et al. Among authors: kulasekararaj a. Hematology. 2024 Dec;29(1):2329030. doi: 10.1080/16078454.2024.2329030. Epub 2024 Mar 21. Hematology. 2024. PMID: 39665683 Free article.
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.
Griffin M, Gandhi S, Kelly RJ, Munir T, Trikha R, Hicks E, Jain D, Ogawa M, Yu J, Muus P, Kulasekararaj AG. Griffin M, et al. Among authors: kulasekararaj ag. Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.285553. Online ahead of print. Haematologica. 2024. PMID: 39605209 Free article.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG; International Consortium on Myelodysplastic Syndromes. Komrokji RS, et al. Among authors: kulasekararaj a. Lancet Haematol. 2024 Nov;11(11):e862-e872. doi: 10.1016/S2352-3026(24)00251-5. Epub 2024 Oct 9. Lancet Haematol. 2024. PMID: 39393368 Review.
199 results